Cargando…
Minimal residual disease in melanoma: circulating melanoma cells and predictive role of MCAM/MUC18/MelCAM/CD146
Circulating tumour cells (CTCs), identified in numerous cancers including melanoma, are unquestionably considered valuable and useful as diagnostic and prognostic markers. They can be detected at all melanoma stages and may persist long after treatment. A crucial step in metastatic processes is the...
Autores principales: | Rapanotti, Maria Cristina, Campione, Elena, Spallone, Giulia, Orlandi, Augusto, Bernardini, Sergio, Bianchi, Luca |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5337524/ https://www.ncbi.nlm.nih.gov/pubmed/28280601 http://dx.doi.org/10.1038/cddiscovery.2017.5 |
Ejemplares similares
-
MCAM/MUC18/CD146 as a Multifaceted Warning Marker of Melanoma Progression in Liquid Biopsy
por: Rapanotti, Maria Cristina, et al.
Publicado: (2021) -
Sequential molecular analysis of circulating MCAM/MUC18 expression: a promising disease biomarker related to clinical outcome in melanoma
por: Rapanotti, Maria Cristina, et al.
Publicado: (2014) -
Stem–Mesenchymal Signature Cell Genes Detected in Heterogeneous Circulating Melanoma Cells Correlate With Disease Stage in Melanoma Patients
por: Rapanotti, Maria Cristina, et al.
Publicado: (2020) -
Galectin-3 Is a Natural Binding Ligand of MCAM (CD146, MUC18) in Melanoma Cells and Their Interaction Promotes Melanoma Progression
por: Pang, Yaoyu, et al.
Publicado: (2022) -
The multifaceted role of CD146/MCAM in the promotion of melanoma progression
por: Lei, Xing, et al.
Publicado: (2015)